Technology 91 of 266
Peptide engineering
6 EIC Accelerator winners build on Peptide engineering, 1% of the classified companies, in 1 sector and 1 industry.
6
Companies
1
Sectors
1
Industries
5
Countries
0%
Exits
33%
Show signs of scaling
Sectors
- Health6 (100%)
Industries
Used together with
Other technologies of the same companies
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Peptide engineering
Show the numbers
| Companies | Peptide engineering | |
|---|---|---|
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 2 | 2 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
What happened to them (6 of 6 checked)
- Active5 (83%)
- Exit0 (0%)
- Failed0 (0%)
- Other1 (17%)
Signs of scaling
- Scaling2 (33%)
- Not scaling1 (17%)
- Scaling unclear3 (50%)
Keywords
- Alpha-lactalbumin
- Bladder cancer
- Blood-brain barrier
- Cancer vaccines
- CD47
- Diffuse midline glioma
- Disease modification
- Extracellular matrix
- Metastasis prevention
- Neurodegeneration
- Neuropathic pain
- Neurotrophic factors
- Non-muscle invasive bladder cancer
- Oncology
- Opioid alternatives
- Paediatric brain tumours
- Pain
- Parkinson's disease
- Postoperative pain
- Prostate cancer
- Tumour microenvironment
All 6 companies using Peptide engineering
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| APMONIA THERAPEUTICS | ACT-MATRIXNovel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering | Biopharmaceuticals | France | March 2024 | Blended finance | Active | Deep dive |
| TAFALGIE THERAPEUTICS | TAFALGIEThe first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance | Biopharmaceuticals | France | June 2023 | Blended finance | Active | Deep dive |
| Gate2brain S.L. | GATE2BRAINGATE2BRAIN. Medicines beyond barriers. | Biopharmaceuticals | Spain | October 2022 | Grant first | Active | Deep dive |
| HERANTIS PHARMA OYJ | ReTreatPDRevolutionary therapeutic treatment for stopping progression of Parkinson's disease | Biopharmaceuticals | Finland | October 2022 | Blended finance | Active | Deep dive |
| Hamlet BioPharma AB | HAMLET-BCAlpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision | Biopharmaceuticals | Sweden | January 2020 | Grant only | Active | Deep dive |
| RHOVAC ApS | RV001RV001: An anti-metastatic cancer vaccine | Biopharmaceuticals | Denmark | June 2019 | Grant only | Pivoted | Deep dive |